Abstract
Pharmacotherapy of obstructive lung disease has improved both quantitatively and qualitatively in recent decades: quantitatively with improvements in adrenergic and methylxanthine drugs and qualitatively with the addition of new classes of drugs, such as steroids, cromolyn, and, most recently, anticholinergic agents. Management of airways disease is based upon several principles: (1) near-normal airways function should be aimed for; (2) long-term, systemic, moderate-to-high-dose corticosteroids should be avoided if at all possible; (3) the judicious use of polypharmacy should be undertaken whenever necessary to provide effective treatment while minimizing drug side effects; and (4) the therapeutic program for a given individual should be tailored to that patient's specific responses to various treatments. Available pharmacologic agents have varying efficacies and adverse effects. The various agents may be used in a number of combinations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
